The Latest Cardiac and Vascular News
NOBLES MEDICAL TECHNOLOGIES II, INC. (NMT2) ANNOUNCED TODAY THE APPROVAL BY THE U.S. FDA OF ITS IDE OF NOBLESTITCH™ EL FOR PFO CLOSURE FOR REDUCTION OF RECURRENT ISCHEMIC STROKE FOUNTAIN VALLEY, Calif., Sept. 5, 2019 /PRNewswire/ — Nobles Medical Technologies II has received approval from the U.S. Food and Drug Administration (USFDA) […]
– TRILUMINATE Pivotal trial is the world’s first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation – There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery – Abbott’s […]
– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial – – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR […]
The Center for Advanced Heart & Vascular Care will transform patient care CLEVELAND — Leaders within University Hospitals and the Harrington Heart & Vascular Institute had a vision to provide the most advanced, efficient and cost-effective medical care to patients with heart and vascular disease. The opening of the […]
SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced that the company has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Shockwave […]
PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant arterial hypertension and heart failure, today announced that it met a new milestone of […]
Durability of Mavacamten’s Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained, Indicative of Potential Improvements in Cardiac Function and Favorable Impact on Long-Term Disease Burden PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 31, 2019 (GLOBE NEWSWIRE) […]
SAN JOSE, Calif. and PARIS, Sept. 3, 2019 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced 12-month results from the Peregrine Post-Market Clinical Trial, which were presented today during a symposium at the 2019 European Society of Cardiology (ESC) Congress in Paris. The Peregrine Post-Market Study is […]
Renowned medical journal publishes the successful clinical results of remote PCI procedures using CorPath® GRX Robotic System technology WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that EClinicalMedicine, a clinical journal published by the nearly 200-year-old medical journal The Lancet, has […]
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes September 1, 2019 – AstraZeneca today announced detailed results from the landmark Phase III DAPA-HF trial that showed FARXIGA (dapagliflozin) on top of standard […]
